Tumour cell-intrinsic CTLA4 regulates PD-L1 expression in non-small cell lung cancer
Author:
Affiliation:
1. Division of Pulmonary and Critical Care Medicine; Department of Medicine; University of California San Diego; La Jolla California
2. Department of Pulmonary Medicine; Zhongshan Hospital; Fudan University; Shanghai China
Funder
American Thoracic Society
NIH/NCI
Publisher
Wiley
Subject
Cell Biology,Molecular Medicine
Link
http://onlinelibrary.wiley.com/wol1/doi/10.1111/jcmm.13956/fullpdf
Reference28 articles.
1. Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti-CTLA-4 antibodies;Peggs;J Exp Med,2009
2. CTLA-4 blockade in tumor models: an overview of preclinical and translational research;Grosso;Cancer Immun,2013
3. Ipilimumab in combination with paclitaxel and carboplatin as first-line treatment in stage IIIB/IV non-small-cell lung cancer: results from a randomized, double-blind, multicenter phase II study;Lynch;J Clin Oncol,2012
4. Pembrolizumab for the treatment of non-small-cell lung cancer;Garon;N Engl J Med,2015
5. Cancer immunology. Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer;Rizvi;Science,2015
Cited by 62 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Production of novel theranostic nano-vector based on superparamagnetic iron oxide nanoparticles/miR-497 targeting colorectal cancer;2024-08-30
2. Transforming growth factor-β1 and soluble co-inhibitory immune checkpoints as putative drivers of immune suppression in patients with basal cell carcinoma;Translational Oncology;2024-04
3. A mesoporous gold biosensor to investigate immune checkpoint protein heterogeneity in single lung cancer cells;Biosensors and Bioelectronics;2024-04
4. The Combination of Anti-CD47 Antibody with CTLA4 Blockade Enhances Anti-Tumor Immunity in Non-Small Cell Lung Cancer via Normalization of Tumor Vasculature and Reprogramming of the Immune Microenvironment;Cancers;2024-02-19
5. From immune checkpoints to therapies: understanding immune checkpoint regulation and the influence of natural products and traditional medicine on immune checkpoint and immunotherapy in lung cancer;Frontiers in Immunology;2024-02-15
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3